Table 1.
Demographical, clinical and MRI characteristics of the subjects included in this study
| Total cases | 220 |
|---|---|
| Demographical data | |
| Age (yrs) | 61.9±9.3 |
| Gender | M: 148 (67%) |
| Tumor locations | |
| Oral cavity | 52 (24%) |
| Oropharynx | 151 (69%) |
| Hypopharynx | 17 (7%) |
| Tumor classification* | |
| T2 | 78 (35%) |
| T3 | 45 (21%) |
| T4 | 97 (44%) |
| Lymph node classification** | |
| N0 | 78 (35%) |
| N1 | 42 (19%) |
| N2 | 97 (44%) |
| N3 | 3 (1%) |
| MRI Sequences | |
| T1 | 220 (100%) |
| T1gad | 213 (97%) |
| STIR | 220 (100%) |
| MR vendors | |
| GE | 104 (47%) |
| Philips | 95 (43%) |
| Siemens | 21 (9%) |
* Tumor classification was defined according to the TNM criteria (7th edition): In general, T2 = the tumor is between 2 and 4 cm in the greatest dimension; T3 = the tumor is larger than 4 cm in the greatest dimension or invading surrounding structures; T4 = the tumor invades other (critical) tissues. ** Lymph node classification was defined according to the TNM criteria (7th edition): N0 = no regional lymph-node metastases; N1 = metastases to one or more ipsilateral lymph nodes with the greatest dimension smaller than 6 cm; N2 = metastases to contralateral or bilateral lymph nodes with the greatest dimension smaller than 6 cm; N3 = metastases to one or more lymph nodes with the greatest dimension larger than 6 cm. Abbreviations: T1gad = contrast-enhanced T1-weighted; STIR = short-T1 inversion recovery